1. FDA Issues 30 Warning Letters to Telehealth Firms Over Misleading Compounded GLP-1 Drug Claims
The U.S. Food and Drug Administration (FDA) has taken regulatory action against 30 telehealth companies for disseminating false and misleading information regarding compounded versions of GLP-1 receptor agonist drugs. These drugs, which include semaglutide and liraglutide, are approved for weight management and type 2 ...